PaverGuide has developed a product called PaverGuide™, an injection-molded, recycled plastic, modular system designed to replace stone as a road base and reservoir below permeable paving. The reservoir allows for infiltration, or beneficial harvesting of storm water.

PaverGuide™ is a structural base for paving systems and exceeds H-20 loading. PaverGuide™ is installed faster and cheaper than the stone it replaces, and at 90 percent void, it provides a large rainwater reservoir and expansive infiltration surface.

Manta Biofuel is a producer of renewable algal crude oil that is cost-competitive with traditional crude oil. The company employs technological advantages in a three-step process to produce crude oil from algae. The first is growing algae. Manta can convert algae from any source, leaving options open from farming to collecting natural blooms. For the second step, harvesting the algae, Manta uses a proprietary magnetic harvester that efficiently collects and concentrates algae. The company then converts the algae to crude oil through hydrothermal liquefaction (HTL).

Firefox Pharmaceuticals is a start-up biotechnology company developing and commercializing a novel class of cholesterol-lowering drugs, creating first-in-class small molecules for reverse cholesterol transport enhancers (RCTE). After nine years of uninterrupted academic research and pharmaceutical R&D, the company has made discoveries in the direct reverse cholesterol transport (RCT) process. Firefox’s strategy tackles all four RCT steps: 1.) increase nascent HDL availabilities; 2.) increase macrophage cholesterol efflux; 3.) increase cholesterol esterification; and 4) increase liver uptake for fecal excretion. Others have focused on strategies to increase HDL (and decrease LDL). Firefox’s quadruple-pronged plan of attack could reduce cholesterol to unprecedented levels by enhancing RCT and eliminating cholesterol already present. The company’s lead compound has showed desired activities, both in vitro and in vivo, for enhanced RCT. A patent application was filed with USPTO on April 3, 2017.

38° North LLC is a fully integrated oyster grow-out company, with activities spanning nursery operations, grow-out, packaging, marketing and the shipping of oysters throughout the United Sates. While modest in size, 38 North is currently one of the largest producers of aquaculture oysters in Maryland.

‍

Maritime Applied Physics Corporation (MAPC) has a 30-year history of designing and building advanced technology systems for both commercial and government sponsors. What began as an engineering services company in the 1980’s has evolved into a research, engineering, and manufacturing company that conceives and builds technology-rich systems. MAPC has a combination of engineering and heavy fabrication capabilities that enable the company to design, prototype and produce innovative systems.

MAPC has specific experience with the design of electronic systems for advanced vehicles, including ground robots, hydrofoils, passenger vessel motion reduction systems, rudder and autopilot systems, watercraft launch and recovery systems, shipboard machinery systems, and unmanned aircraft launch and recovery systems. The company has an excellent capability to perform the dynamic simulations of control problems and design and implement digital controls for these systems. MAPC has built and supplied inertial navigation systems and robotic control systems on land, air and sea vehicles. The company has built electric vehicles for a major car company.

N5 Sensors, a University of Maryland spin-off founded by UMD Research Scientist Abhishek Motayed, is commercializing a new generation of chip-scale chemical sensors that can detect harmful chemicals mixed in air, such as industrial chemicals, automobile exhausts, cigarette smoke, and pollutants released from paints, cleaners, pesticides and other products. These new sensors, built using the same fabrication processes that are commonly used for silicon computer chips, are small and accurate, with the capability to detect multiple gases at the same time. N5 is working to develop arrays of multi analyte sensors on a single chip, which can be integrated with smart phones, allowing industrial workers, first-responders, and soldiers to assess the dangers of their surroundings rapidly and accurately in real-time using their smart phones.

Medcura (formerly gel-e Inc.), a privately held, clinical-stage medical device company, develops a broad range of hemostatic and wound treatment products, including bandages for the treatment of routine cuts and scrapes, foams and putties for traumatic and military injuries, and surgical gels and powders.

Artgen Inc. develops novel, non-viral gene therapies for the treatment of vascular diseases. The company’s lead product candidate, ART-101, is a DNA plasmid designed to be delivered directly to the site of injured tissue, with the first indication directed for peripheral artery disease (PAD). Currently, there are no approved drugs for the treatment of PAD, a disease that can ultimately lead to lower limb loss and functionality. ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis (the development of new blood vessels). Artgen’s platform technology could potentially treat additional vascular diseases.